Skip to main content

Pharma/Regulatory

stop.smoking.jpg

Rheumatoid Arthritis Patients Need to Quit Smoking ASAP

Oct 04, 2022

While it is known that smoking ups the risk of developing RA, its effect on outcomes in those with established rheumatoid arthritis (RA) is less known.  A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.

Read Article
death

Causes of Death in Lupus

Oct 03, 2022

The California Lupus Surveillance Project has longitudinally followed included systemic lupus erythematosus (SLE) cases and shown that overall, the leading cause of death was cardiovascular disease (CVD), followed by rheumatic disease and hematologic/oncologic conditions.

Read Article
choices2.jpg

IL-17 Switching Works in Psoriatic Disease

Oct 03, 2022

Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.

Read Article
coronavirus,COVID,MISC,mask

COVID-19 Arthropathy and Myalgia

Sep 30, 2022

An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.



Like other alphaviruses, the coronavirus has been reported to result in numerous musculoskeletal complaints. Researchers assessed the prevalence of

Read Article
narcotic%20pills.jpg

Opioid Crisis Costs USA $1.5 Trillion

Sep 29, 2022

Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.

Read Article
JAK Janus

Efficacy and Safety of JAK Inhibitors in Psoriatic Disease

Sep 28, 2022

There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe psoriasis and psoriatic arthritis, according to a systematic review in BMC Rheumatology.

Read Article
PMR2.jpg

Is PMR the Next Indication for Tocilizumab?

MedPage Today
Sep 21, 2022

About half of patients with steroid-dependent polymyalgia rheumatica (PMR) were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, which also improved disease control in most cases, a randomized phase III trial showed.



In a 24-week study, 49

Read Article
USA,States,map

ACR's State-by-State Report Cards for Rheumatic Disease

Sep 19, 2022

New report examines access, affordability, and activity and lifestyle factors in all 50 states and the District of Columbia, evaluating how easy it is to live with a rheumatic disease in your state. No state scored an "A" or "F", and only two states improved their 2018 grades.

Read Article
cancer.melanoma.jpg

Does Methotrexate Use Lead to Melanoma?

Sep 15, 2022

A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible.

Read Article
FDA,approved,stamp,blue

First In Class, TYK2 Inhibitor FDA Approved for Psoriasis

Sep 12, 2022

Deucravacitinib (Sotyktu), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.

Read Article
RheumNow Podcast square

Does Fibromyalgia Need B12? (9.9.2022)

Sep 09, 2022

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.

Read Article
SLE,malar,black

Does Dendritic Cell Targeted Therapy Work in SLE?

Sep 08, 2022

A phase 2 trial using litifilimab, a humanized monoclonal antibody binding to blood dendritic cell antigen 2 (BDCA2), demonstrated clinical efficacy in adults with systemic lupus erythematosus (SLE).



By targeting BDCA2 on plasmacytoid dendritic cells, researchers were able to

Read Article
IPF.lancet.jpg

Pirfenidone Potential in RA-Related Lung Disease

MedPage Today
Sep 07, 2022

Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial, researchers reported here and in a simultaneous journal publication.

Read Article
Rheumatoid,RA,nodules,damage

Global Trends Informing the Future of Rheumatoid Arthritis

Sep 06, 2022

Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time. 



The article appears in Nature Reviews Rheumatology and discusses worldwide variance

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Voclosporin Efficacy and Safety in Lupus Nephritis

Sep 05, 2022

An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.



at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids

Read Article
RheumNow Podcast square

Goofy But True

Sep 02, 2022

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.




  1. After historic drop in 2020 (COVID), life expectancy in USA dropped again,

Read Article
genes_0.jpg

Genetic Testing for Autoinflammatory Disease

Sep 01, 2022

Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.

Read Article
virus,injection,COVID,vaccine

FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines

Aug 31, 2022

Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. The BA.5 subvariant accounts for more than 88% of U.S. infections.

Read Article
MTP1,gout

NICE Guidelines on Gout Diagnosis and Management

Aug 31, 2022

NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.

Read Article
IL-6 IL6 cells cytokine

Olokizumab, another IL-6 Inhibitor for RA

Aug 25, 2022

This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.

This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6

Read Article
joint.injx_.jpg

Hyaluronic Acid Knee Injections Equivalent to Placebo

Aug 25, 2022

In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.



BMJ has published a metanalysis of the efficacy and safety of viscosupplementation (intraarticular

Read Article
SI AS SpA ACR

Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis

Aug 22, 2022

A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.



Researchers examined two PsA and AS cohorts -  patients with PsA with axial disease and isolated axial patients with AS with

Read Article
RheumNow Podcast square

Managing JDM with Calcinosis

Aug 19, 2022

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.




  1. CDC report of fungal infx in US 2019 - coccidioidomycosis (20,061), histoplasmosis (1,124) & blastomycosis (240

Read Article
JIA_0.jpg

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA

Aug 16, 2022

JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.

Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Aug 05, 2022

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.




  1. 521 clinically suspect arthralgia (CSA) pts were

Read Article
×